Ionis Pharmaceuticals Inc. has announced a proposed private offering of $700 million aggregate principal amount of Convertible Senior Notes due 2030. The company also plans to grant initial purchasers an option to buy up to an additional $70 million principal amount of notes within a 13-day period starting from the initial issuance date. The notes will be general unsecured obligations of Ionis and will accrue interest payable semiannually in arrears. Upon conversion, Ionis may settle the notes in cash, common stock, or a combination of both, at its discretion. The interest rate, initial conversion rate, and other terms will be determined at the time of pricing. Proceeds from the offering are expected to be used for repurchasing or repaying the company's 0% Convertible Senior Notes due 2026. No URL for the full prospectus is included in the document.